Biocon, Dr. Reddy's, Intas Plan Biosimilars Of Roche's Herceptin
This article was originally published in PharmAsia News
Executive Summary
Biocon, Dr. Reddy's Laboratories and Intas Pharma are expected to take advantage of Roche's loss of certain Herceptin (trastuzumab) patents and launch their own versions of the breast-cancer treatment.